Found: 238
Select item for more details and to access through your institution.
Novel Therapeutic Avenues in Myeloma: Changing the Treatment Paradigm.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 7, p. 785
- By:
- Publication type:
- Article
New Treatments for Multiple Myeloma.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 14, p. 1781
- By:
- Publication type:
- Article
Treatment Options and Considerations for the Newly Diagnosed Myeloma Patient.
- Published in:
- 2005
- By:
- Publication type:
- Report
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.
- Published in:
- Journal of Biomedical Optics, 2011, v. 16, n. 1, p. 011006, doi. 10.1117/1.3520571
- By:
- Publication type:
- Article
JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
- Published in:
- Journal of Pharmacy & Pharmacology, 2010, v. 62, n. 1, p. 145, doi. 10.1211/jpp.62.01.0017
- By:
- Publication type:
- Article
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01019-5
- By:
- Publication type:
- Article
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00955-y
- By:
- Publication type:
- Article
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Novel therapies in MM: from the aspect of preclinical studies.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Apoptotic signaling in multiple myeloma: therapeutic implications.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Novel biologically based therapies for multiple myeloma.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine.
- Published in:
- 2001
- By:
- Publication type:
- Book Review
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
- Published in:
- 2013
- By:
- Publication type:
- journal article
BM mesenchymal stromal cell--derived exosomes facilitate multiple myeloma progression.
- Published in:
- Journal of Clinical Investigation, 2013, v. 123, n. 4, p. 1542, doi. 10.1172/JCI66517
- By:
- Publication type:
- Article
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
- Published in:
- Journal of Clinical Investigation, 2013, v. 123, n. 3, p. 1542, doi. 10.1172/JCI66517
- By:
- Publication type:
- Article
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs.
- Published in:
- Clinical & Experimental Medicine, 2023, v. 23, n. 7, p. 3821, doi. 10.1007/s10238-023-01124-y
- By:
- Publication type:
- Article
Leukocyte reduction in blood component therapy.
- Published in:
- 1992
- By:
- Publication type:
- journal article
Reducing the risk for transfusion-transmitted cytomegalovirus infection.
- Published in:
- 1992
- By:
- Publication type:
- journal article
Transfusion-Acquired Human Immunodeficiency Virus Infection Among Immunocompromised Persons.
- Published in:
- Annals of Internal Medicine, 1986, v. 105, n. 4, p. 519, doi. 10.7326/0003-4819-105-4-519
- By:
- Publication type:
- Article
Acute Myelocytic Leukemia in Two Brothers with Polyposis Coli and Carcinoma of the Colon.
- Published in:
- 1981
- By:
- Publication type:
- Case Study
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
- Published in:
- Biologics: Targets & Therapy, 2008, v. 2, n. 3, p. 419
- By:
- Publication type:
- Article
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, v. 16, p. 1, doi. 10.1177/17588359231221340
- By:
- Publication type:
- Article
Dizygotic twinning, cryptorchism, and seminoma in a sibship.
- Published in:
- 1984
- By:
- Publication type:
- journal article
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
- Published in:
- Nature Medicine, 2014, v. 20, n. 6, p. 599, doi. 10.1038/nm.3562
- By:
- Publication type:
- Article
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
- Published in:
- Nature Medicine, 2010, v. 16, n. 4, p. 483, doi. 10.1038/nm.2112
- By:
- Publication type:
- Article
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 3, p. 496, doi. 10.1111/bjh.17338
- By:
- Publication type:
- Article
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 4, p. 495, doi. 10.1111/bjh.15384
- By:
- Publication type:
- Article
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 2, p. 222, doi. 10.1111/bjh.15261
- By:
- Publication type:
- Article
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 4, p. 433, doi. 10.1111/bjh.15116
- By:
- Publication type:
- Article
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 5, p. 756, doi. 10.1111/bjh.14974
- By:
- Publication type:
- Article
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 6, p. 929, doi. 10.1111/bjh.14493
- By:
- Publication type:
- Article
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 5, p. 711, doi. 10.1111/bjh.14113
- By:
- Publication type:
- Article
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 3, p. 397, doi. 10.1111/bjh.14065
- By:
- Publication type:
- Article
Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.
- Published in:
- British Journal of Haematology, 2016, v. 173, n. 1, p. 82, doi. 10.1111/bjh.13928
- By:
- Publication type:
- Article
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 5, p. 798, doi. 10.1111/bjh.13780
- By:
- Publication type:
- Article
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 6, p. 843, doi. 10.1111/bjh.13382
- By:
- Publication type:
- Article
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 6, p. 851, doi. 10.1111/bjh.13383
- By:
- Publication type:
- Article
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 3, p. 401, doi. 10.1111/bjh.12909
- By:
- Publication type:
- Article
Identification of human leucocyte antigen ( HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA- DOβ as a novel target for multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 3, p. 343, doi. 10.1111/bjh.12544
- By:
- Publication type:
- Article
TRIM13 ( RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 2, p. 210, doi. 10.1111/bjh.12365
- By:
- Publication type:
- Article
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
- Published in:
- Nature Methods, 2005, v. 2, n. 5, p. 357, doi. 10.1038/nmeth759
- By:
- Publication type:
- Article
Targeting the UPS as therapy in multiple myeloma.
- Published in:
- BMC Biochemistry, 2008, v. 9, p. 1, doi. 10.1186/1471-2091-9-S1-S1
- By:
- Publication type:
- Article
Autologous peripheral blood progenitor cell transplantation.
- Published in:
- Journal of Clinical Apheresis, 1995, v. 10, n. 3, p. 131, doi. 10.1002/jca.2920100307
- By:
- Publication type:
- Article
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 523, doi. 10.1002/ajh.27207
- By:
- Publication type:
- Article
Interpretation klinischer Studiendaten zum Multiplen Myelom: Übertragung der Ergebnisse auf die klinische Praxis.
- Published in:
- Kompass Onkologie, 2019, v. 6, n. 1, p. 10, doi. 10.1159/000497022
- By:
- Publication type:
- Article
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.
- Published in:
- Experimental Hematology & Oncology, 2017, v. 6, p. 1, doi. 10.1186/s40164-017-0081-6
- By:
- Publication type:
- Article
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01821
- By:
- Publication type:
- Article
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01822
- By:
- Publication type:
- Article
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
- Published in:
- PLoS ONE, 2015, v. 10, n. 12, p. 1, doi. 10.1371/journal.pone.0143847
- By:
- Publication type:
- Article